drugset
drugset / Trial / NCT05862090

A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers

NCT05862090 ↗

Phase 1 Completed 40 enrolled Hanmi Pharmaceutical Company Limited
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug-drug interaction and safety of RLD2301 and RLD2007 after oral administration in healthy volunteers.

Timeline

Start
2023-04-05
Primary completion
2023-05-26
Completion
2023-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject RLD2007 Unknown — Oral
Subject RLD2301 Unknown — Oral

Indications

No indication recorded.